Development of mucosal vaccine against obesity-associated intestinal bacteria

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K17932
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 54030:Infectious disease medicine-related
• Research Institution: Osaka City University
• Principal Investigator: Fujimoto Kosuke 大阪市立大学, 大学院医学研究科, 助教 (30802805)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: 腸内細菌 / 粘膜ワクチン / Clostridium ramosum / IgA

Outline of Final Research Achievements

We developed mucosal vaccines against Clostridium ramosum, which have been reported to be associated with obesity and diabetes in human, and showed that administration of the mucosal vaccines improve the pathophysiology of obesity and diabetes. In addition, the base of the vaccines were modified to use for humans. Using Animal models, we showed the safety and efficacy of the mucosal vaccines based on a water-in-oil-in-water emulsion.

Free Research Field

免疫学、ゲノム微生物学

Academic Significance and Societal Importance of the Research Achievements

さまざまな疾患と関連する腸内共生病原菌を特異的に制御する方法が強く求められている。新しく開発した粘膜ワクチンを肥満や糖尿病に関わる腸内共生病原菌Clostridium ramosumに応用したところ、効率的な粘膜免疫応答が誘導とともに、Clostridium ramosumが引き起こす肥満や糖尿病の病態を著しく改善させることができた。腸内共生病原菌が関連する疾患に対する新たな予防・治療アプローチとなる可能性がある。